Compare

Doximity/$DOCS

1D1W1M3M6MYTD1Y5YMAX

About Doximity

Doximity Inc provides an online platform, which enables physicians and other healthcare professionals to collaborate with colleagues, stay up to date with the latest medical news and research, manage their careers and on-call schedules, streamline documentation and administrative paperwork, and conduct virtual patient visits. The Company's customers include pharmaceutical companies and health systems that connect with healthcare professionals through the Company's digital Marketing, Hiring, and Workflow Solutions. Marketing Solutions provide customers with the ability to share tailored content on the network. Hiring Solutions enable customers to identify, connect with, and hire from the network of both active and passive potential medical professional candidates.
Ticker
$DOCS
Sector
Health
Primary listing
NYSE
Employees
880

Doximity Metrics

BasicAdvanced
$5.6B
43.18
$0.72
1.29
-

What the Analysts think about Doximity

Analyst ratings (Buy, Hold, Sell) for Doximity stock.
Analyst projections of the future price of Doximity stock.

Bulls say / Bears say

Doximity’s workflow tools are gaining traction: active workflow prescribers rose more than 30% year on year, while AI search queries grew over 25% quarter on quarter. Greater use gives the company more opportunities to monetise its physician network. (SEC)
Early commercial AI Search economics look promising: management said revenue per search was more than ten times the cost to serve it, and the first customer programmes were being onboarded. Longer, larger contracts could make AI Search a meaningful new revenue stream if this early interest converts. (CNBC, The Motley Fool)
Hospital uptake gives Doximity a potential growth channel beyond pharmaceutical advertising: it had signed 165 health-system AI clients and was expanding its clinical tools across hospital workflows. Enterprise deployments could make Ask and Scribe more embedded in clinicians’ daily work. (Fierce Healthcare)
Near-term growth remains subdued: management’s fiscal 2027 revenue guidance implies about 5% growth, and its second-quarter outlook implies roughly 1%. Tight pharma budgets and shorter customer commitments limit visibility into a faster recovery. (The Motley Fool)
AI investment is already pressuring profitability: first-quarter revenue rose 7%, but adjusted EBITDA fell 6% and net income dropped to $24.3 million from $53.3 million a year earlier. The company also expects elevated AI-related costs to weigh on margins during the year. (SEC, SEC)
The shares may leave little room for execution errors: Wells Fargo argued that Doximity’s valuation reflected compounder-level expectations despite market-like growth, while AI monetisation remained unproven. If the new products do not accelerate growth, that gap could weigh on the stock. (Yahoo Finance)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

Doximity Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Doximity Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.